Amenorrhea and galactorrhea: results of therapy with 2-Brom-alpha-ergocryptine (CB-154).
Administration of Brom-ergocryptine (CB-154) has a dramatic effect on breast secretion. Inhibition of lactation occurs within three to four weeks in women with amenorrhea and galactorrhea. Resumption of normal ovulatory function was documented by serum progesterone levels, as well as pregnancy, in three of four women attempting to conceive. Serum prolactin levels become normal following initiation of Brom-ergocryptine. Discontinuation of Brom-ergocryptine was found to result in a return of both inappropriate lactation and elevation of serum prolactin in this study. No deleterious side effects of Brom-ergocryptine have been found in any of the volunteers either clinically or on the basis of sequential laboratory studies.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D001942:Breast Feeding; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005687:Galactorrhea / Q000188:drug therapy*; D006801:Humans; D007774:Lactation / Q000187:drug effects; D007775:Lactation Disorders / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D011863:Radioimmunoassay
D004873:Ergolines; D001971:Bromocriptine; D011374:Progesterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone